A Worcester man was part of the Pfizer COVID vaccine trial, but didnt get the actual shot; His experience an – MassLive.com

February 5, 2021 medical

When Paul Bolton, of Worcester, learned he was part of the placebo-controlled group in Pfizer-BioNTechs COVID vaccine trial, he was anxious to find out how long hed have to wait to actually get immunized.

I wanted to see if I could get the vaccine as soon as possible, Bolton, who is a prosecutor for the Worcester District Attorneys office, said.

Bolton, who is in his late 60s, was one of 131 trial participants enrolled in the study, which began in July 2020, through UMass Medical School. With COVID-19 sweeping across parts of the south and the Midwest, and with several prototype vaccines in production, the Worcester native says he just wanted to help in whatever way possible.

He responded to a call for participants in the trial posted on social media, and UMass Medical School contacted Bolton the same day. After being screened for COVID and having blood drawn, he received an injection that he suspected, not long after, was saline not the real thing.

They say if you got the vaccine, you get a kind of a cold feeling going into your arm, Bolton said. I didnt get that so I was pretty sure I had the placebo.

On Jan. 14, the college reached out to Bolton to let him know he was part of the placebo-controlled group during the trial, meaning he didnt actually receive the Pfizer vaccine. The placebo group is used to measure the results of those who did get the COVID vaccine the difference in, for example, immune system response, and other side effects.

Five days later, he got his first dose of the vaccine, which Bolton surmised was well ahead of schedule, according to the states timeline. He has an appointment scheduled for the second dose on Feb. 12.

Now that hes on the verge of being fully vaccinated, Bolton says he feels like a burdens been lifted. Per the trial, he will continue reporting any symptoms or side effects to the UMass researchers.

There were concerns last year over about the integrity of the vaccines ahead of trials during what was to become an expedited emergency approval process. Health experts had high hopes for the shots which, if effective, would have far-reaching consequences for the U.S. and the rest of the world.

We didnt know if theyd work, and we didnt know if it was safe, Dr. Douglas T. Golenbock, chief of the Division of Infectious Diseases and Immunology at UMass Medical School, said of the Pfizer vaccine. But thats the nature of clinical trials.

The pace of the development of mRNA COVID vaccines (approved on an emergency basis in under a year of the virus taking root in the U.S.) and the sheer scale of their preliminary testing remains an unprecedented public health project. With the trials still ongoing, and with other companies working on their versions of vaccines in the middle of a national rollout, some experts worry about how willingly the public will participate in future trials and studies.

As we get closer to the time when people think they will get their vaccination, some are going to say, Yeah, Ill just wait it out, rather than take the risk, Dr. Eric Rubin, editor-in-chief of the New England Journal of Medicine and professor in the Department of Immunology and Infectious Diseases at Harvard University, said. Thats inherent in having a simultaneous testing and rollout strategy.

Rubin says experimental trials typically generate more enthusiasm among those who sign up. That tends to wane over time.

And in the case of COVID vaccine testing, the more people are vaccinated, the harder it may become for other companies to recruit volunteers.

That might limit the development of vaccines that are very late to the game, Rubin said. Youre tapping into groups of people who are less and less excited.

Pfizer recently said it finished enrolling children aged 12 to 15 in a new clinical trial to gauge the efficacy of the shots in children. The Pfizer vaccine is currently approved only for adults over the age of 16. The Moderna vaccine, similarly, is only approved for adults older than 18.

FDA weighs tighter restrictions for Pfizer’s Xeljanz on the heels of safety red flags – FiercePharma

February 5, 2021 medical

The FDA already has restrictions on the use ofPfizers JAK inhibitor Xeljanz at a higher dose because of safety concerns. Now, thanks to new red flags, the agency is weighing a move to tighten those restrictions.

In a post Thursday, the FDAalertedpatients and doctors that a postmarket study has linked Xeljanz to an increased risk of serious heart-related problems and cancer compared with TNF inhibitors, a group that includes such drugs as AbbVies Humira. The problems applied to both the 5-mg twice-daily dose and the higher 10-mg strength.

The agency said itll evaluate the clinical trial results and consider what moves to take. The last time it made that kind of comment, it wound up puttinga boxed warning on the high dose and strippingit of its use in previously untreated ulcerative colitis.

In the meantime, the FDA asks patients not to stop taking Xeljanz without first consulting with their doctors.

The FDAs announcement came days after Pfizer unveiled the data from the postmarket trial, which were required by the FDA in granting Xeljanz its first go-ahead in rheumatoid arthritis in 2012.

In the trial ofabout 4,400 rheumatoid arthritis patients who were at least 50 years old and had at least one cardiovascular risk factor, the rate of major cardiovascular events was higher for Xeljanz takers at 3.37%, versus 2.55% for the TNF group. Cancers developed in 4.19% of Xeljanz patients, also higher than the 2.89% among TNF receivers.

RELATED:Pfizer's Xeljanz fails RA safety study, making a tough rivalry with AbbVie's Rinvoq even tougher

Pfizer first warned of heart-related safety issues tied to the trials 10-mg Xeljanz dose in 2019. The FDA took note, slappinga warning label on the drugpointing to an increased risk of blood clots and death. The European Medicines Agency followed with a similar but slightly different restriction.

But the regulatory red alert doesnt affect Xeljanzs larger rheumatoid arthritis indication, because the high dosing regimen is only meant for ulcerative colitis patients. In fact, Xeljanz, as Pfizers cornerstone immunology product, managed to grow sales by 9% at constant currencies to $2.4 billion in 2020, with U.S. prescription volume rising 12% year over year, Pfizer CEO Albert Bourla, Ph.D., said on the companys fourth-quarter earnings call Tuesday.

But its different this time. As the trials raised red flags for both those doses, all three existing Xeljanz indicationswhich also include psoriatic arthritisas well as a potential nod in ankylosing spondylitis could be under threat.

RELATED:Pfizer may have a lot going on in immunology, but all its drugs could be beaten by rivals: analyst

During the call, Pfizer management defended Xeljanzs place in those markets. Pfizer R&D chief Mikael Dolsten, M.D., Ph.D., said the postmarket trial participants belong to a unique population with increased severe risk, pointing to other clinical trial and real-world data it had accrued in larger patient groups.

As for the implications of the study on Xeljanz's label, Pfizer said its still too early to call. We still have a lot of work to do in terms of secondary endpoints, subpopulations and bringing all of this together to discuss this with regulators. So I think were still a ways off in terms of really understanding what impact it will be to our label, Angela Hwang, Pfizers biopharma president, said during the call.

Xeljanzs problems could hand fellow JAK inhibitors,such as AbbVies newly launched Rinvoq, an advantage. Although there are some concerns over potential scrutiny across the entire class, Rinvoq hasnt shown any imbalanced cardiovascular safety signals in the clinic. Pfizer also argued against reading Xeljanzs data into other JAK programs, mainly from the standpoint of its own follow-on programs such as abrocitinib, which is under FDA priority review in atopic dermatitis.

Excerpt from:
FDA weighs tighter restrictions for Pfizer's Xeljanz on the heels of safety red flags - FiercePharma

Immunology

Jnana Therapeutics Expands Leadership Team with Two Experienced Biopharmaceutical Executives – BioSpace

February 5, 2021 medical

Feb. 3, 2021 12:00 UTC

Company appoints Nick Pullen, PhD, as Senior VP, Head of Biology and Brian Danieli as VP, Head of Finance & Operations

BOSTON--(BUSINESS WIRE)-- Jnana Therapeutics, a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced that it has expanded its leadership team with the appointment of two accomplished biopharmaceutical executives: Nick Pullen, PhD, as Senior Vice President, Head of Biology, and Brian Danieli as Vice President, Head of Finance and Operations. These new executives join Jnana at a significant time in the companys evolution as it advances its first SLC transporter-targeted therapies toward clinical development.

Nick Pullen, PhD, Senior Vice President, Head of Biology

Nick is an experienced and passionate leader in drug discovery and development with deep knowledge in several therapeutic areas, including renal disease and inflammation, that are highly relevant to our R&D work with SLC transporters, said Joel Barrish, PhD, co-founder and Chief Scientific Officer of Jnana Therapeutics. We are delighted to welcome Nick to our team and look forward to his contributions in building our research and development strategy and helping guide our lead programs toward the clinic.

In the role of Senior Vice President, Head of Biology, Dr. Nick Pullen will work to further leverage Jnanas RAPID platform to systematically target SLC transporters and develop novel small molecule drug candidates. Dr. Pullen is an experienced drug discovery and development leader with 20 years of experience and a proven track-record of therapeutic innovation across multiple disease areas. Before joining Jnana, he was Vice President, Integrative Sciences, Inflammation & Immunology, Cardiovascular & Fibrosis, at Bristol Myers Squibb and prior to this, he served as Executive Director, Inflammation & Immunology for Celgene. In both of these roles, Dr. Pullen was responsible for scientific and strategic leadership of externalized drug discovery programs applying novel technologies and scientific insights to the expansion of the Inflammation & Immunology portfolio as well as more broadly. Dr. Pullen brings extensive experience in Inflammation & Fibrosis, following a career at Pfizer which spanned more than 15 years and brought multiple development candidates to clinical evaluation and touched many disease areas including renal disease, IBD and NASH, a breadth of experience with significant pertinence to the emerging Jnana portfolio. Dr. Pullen received his PhD in biochemistry from the University of Southampton in the UK.

The Jnana team have made remarkable progress in the development of technologies that open up the therapeutic opportunity afforded by targeting the SLC gene family. I am thrilled to be joining Jnana at this exciting stage in the companys growth and to help them build a pipeline of small molecules targeting SLC transporters, said Dr. Pullen.

Brian Danieli, Vice President, Head of Finance & Operations

Brians extensive finance background and expertise will be a critical addition to the organization, said Caroline Stark Beer, Jnanas Chief Business Officer. Were very pleased to welcome Brian to Jnana and look forward to Brians financial and operational leadership as we enter a new stage of growth.

As the Head of Finance and Operations of Jnana Therapeutics, Brian Danieli will expand the companys finance and operations infrastructure to allow for growth to a clinical-stage drug developer. Mr. Danieli is an expert finance leader with more than 20 years of global experience with fast-growing biotechnology companies. He joins Jnana from Momenta Pharmaceuticals, where he led Financial Planning & Analysis. Previously, he served for more than 20 years in roles of increasing responsibility at Sanofi Genzyme. His most recent position at Sanofi Genzyme was Head of Finance for North America Rare Disease and Rare Blood Disorders, and he drove all aspects of strategic financial planning and operations for the North American region for two business units representing $2B in combined sales with over 500 employees and 12 products. In his roles at Sanofi Genzyme, Mr. Danieli spearheaded the integration of Bioverativ and Ablynx acquisitions, implemented financial modeling and assembled franchise performance metrics for investor audiences. Earlier in his career, he held financial positions at Blue Cross Blue Shield of Massachusetts and KPMG. He earned a BS in accounting from Boston College.

I am eager to leverage my experience to support Jnanas evolution in the next stage of its business, said Mr. Danieli. I see tremendous potential for Jnanas platform to bring innovation to a range of diseases, and I am excited to be part of a team that is committed to bring novel medicines to make a difference in the lives of patients.

About Jnana Therapeutics

Jnana Therapeutics is a biotechnology company focused on opening the solute carrier (SLC) family of metabolite transporters as a target class to develop transformational therapeutics. Jnana uses its RAPID platform, a proprietary, cell-based drug discovery approach, to systematically target SLC transporters and develop best-in-class therapies to treat a wide range of diseases, including immune-mediated, neurological and metabolite-dependent diseases. Headquartered in Boston, Jnana is founded by world-renowned scientists and backed by leading life science investors. For more information, please visit http://www.jnanatx.com and follow us on Twitter and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005102/en/

See the original post:
Jnana Therapeutics Expands Leadership Team with Two Experienced Biopharmaceutical Executives - BioSpace

Genetics

What 23andMe’s filing to go public says about the big genetics business – STAT

February 5, 2021 medical

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Go here to see the original:
What 23andMe's filing to go public says about the big genetics business - STAT

Genetics

Evenings with Genetics: Race and Genetics | BCM – Baylor College of Medicine News

February 5, 2021 medical

Do racial categories obscure our genetic similarities and differences? How do we quantify ancestry and is it important in precision medicine? This month, Baylor College of Medicine is hosting two Evenings with Genetics webinars to address these questions and other issues involving race and genetics.

The webinars will take place on Tuesday, Feb. 9, and Tuesday, Feb. 16, at 7 p.m. CST. Both sessions will address the role of race in genetic research and clinical care, as well as racial justice and bioethics in precision medicine.

This series focused on race and Black history is exciting and timely, said Dr. Debra Murray, assistant professor of molecular and human genetics at Baylor and co-organizer of the event. The invited speakers will bring to light several areas where genetics has been influenced by race. In order to pursue social justice, we must ensure science without bias. People with non-European ancestry should not be prevented from enjoying the promise of precision medicine.

The 15th anniversary of this series is the perfect opportunity to offer our community these discussions on the perception of race as we strive to ensure precision medicine is available to all, said Susan Fernbach, assistant professor of molecular and human genetics at Baylor and co-organizer of the event.

Panelists on Feb. 9 include Dr. Charmaine Royal, professor of African & African American studies, biology, global health and family medicine and community health at Duke University, Dr. Clayton Yates, professor in the Department of Biology and Center for Cancer Research at Tuskegee University, and Shawneequa Callier, associate professor in the Department of Clinical Research and Leadership at the George Washington University School of Medicine and Health Sciences.

Panelists on Feb. 16 include Dr. Rick Kittles, professor and director of the Division of Health Equities in the Department of Population Sciences at City of Hope, Dr. Charmita Hughes-Halbert, professor in the Department of Psychiatry and Behavioral Sciences at Medical University of South Carolina, and patient advocate J.H. Jones.

The program is free and open to the public, but registration is required. A Zoom link will be sent to all registered participants. For more information, call 713-798-8407 or visit the event registration pages for Feb. 9 and Feb. 16. Videos of both sessions will be available online here at a later date.

This event is sponsored by the Department of Molecular and Human Genetics, the Office of Diversity, Equity and Inclusion, the Human Genome Sequencing Center and Baylor Genetics.

See the original post here:
Evenings with Genetics: Race and Genetics | BCM - Baylor College of Medicine News

Genetics

From Ancestry to Genetics-Based Drug Development, Richard Branson Takes 23andMe Public – BioSpace

February 5, 2021 medical

Billionaire Sir Richard Branson believes in healthcare. This week he put more of his money where his mouth is by using his SPAC to take consumer DNAtesting company23andMepublic in a massive deal.

At Virgin, we try to partnerwith companies that can make a real difference in the world like healthcare companies...saidBransonin an interview.

The essentially reverse merger delivers $759 million to 23andMe and bumps up the companys value to $3.5 billion.Launched in2006,for most, it was a neat way to find out who youare, who your ancestors were, where they came from, and even your genetic predispositions that put you at higher risk for certain diseases.But the company has grownintoevenmore than that.

Ancestry and health have always been key components of the product but more and more the future is the health side. How is it that you can get your genetic information and really benefit from the Human Genomeand life a healthier life?saidCEOand co-founderAnne Wojcicki.

Its these exciting opportunities in the healthcare aspect that convinced Branson the company was ripe for his next big investment.

23andMe, for instance, just their drug development side could shorten the development of a new drug using allthe knowledge that theyve gained over the last twelve years by as much as 3 years which makes coming up with drugs that much quicker, said Branson.

Both Branson and Wojcicki personally contributed $25 million to the deal. Branson was also an early investor in the company, having contributed to 23andMes Series A.

23andMes first program,Move Forward, is now in humantrialswithpartnerGlaxoSmithKline.Theimmuno-oncologyprogram was GSKs, validated by 23andMes proprietary algorithm.Wojcicki was tightlippedfor nowon the timeline for any data.

If you think back on our mission statement, its about helping customers access, understand and benefit from the Human Genome. And the key thing that were doing right now is helping our customers benefit. Theyregoing to benefit in two ways. One is they are going to be empowered with information to help them live a healthier life. And second is on the therapeutic side. 23andMe is working hard to say how do we analyze all this data? How do weunderstand those genetics so we can develop very personalized therapeutics that could potentially cure diseases, saidWojcicki.

All data studied as part of the collaboration with GSK and all 23andMe research is from customers who opted-in to a separate research consent. Privacy is a majorconcern for consumers in todays data age.

Last January,Spanish pharma companyAlmirallin-licensed a bispecific monoclonal antibodyfrom 23andMethat blocksallmembers of the IL-36 cytokinesubfamily. Associated with multiple inflammatory diseases and dermatological conditions, Almirall is developing and commercializing the antibody for global use.

Window into the genetics behind equine reproduction grows ever wider, say researchers – Horsetalk

February 5, 2021 medical

The genetic origins behind reproductive traits are still far from clear, and this is especially so for horses, researchers say. Photo by Phinehas Adams

The knowledge of the reproductive architecture of horses on a genetic level is likely to grow considerably over the next few years, the authors of a just-published review predict.

The genetic origins behind reproductive traits are still far from clear, and this is especially so for horses.

Nora Laseca and her colleagues, writing in the journal Animals, said reproductive traits are complex and usually determined by multiple genes.

They also have low heritability, which makes them particularly sensitive to environmental and management factors, such as age, nutrition, training, temperature at mating, and breeding season.

By that reason, modeling reproductive traits from a genetic point of view is difficult, they wrote in their review of recent advances and studies analyzing genomic mechanisms affecting reproductive function in mares and stallions.

This is particularly important in equines, whose fertility is considerably lower than that observed in other domestic species, they said.

In addition, equine reproductive efficiency is limited by their own physiology, characterized by single births in almost all the foalings, seasonality in mares, long generation intervals delaying genetic improvement, and a lack of systematized collection of phenotypic information reproductive traits.

Nevertheless, a certain degree of genetic influence has been described and modelized from a quantitative viewpoint, in mares and stallions.

For instance, gestation length in mares is affected by maternal lineage or inbreeding, while changes in sperm traits are related to the genetic background of the individual, lineage and breed, as well as by the inbreeding value.

However, there are very few reports which describe the molecular mechanisms involved in such genetic influence or which detect the candidate genes involved in the biological processes.

The advent of genomics has led to the development of new approaches to genetic analysis in livestock, including the detection of specific mutations and other genetic issues.

However, their use in equines is still limited, probably due to the delay in the development of a reliable reference genome, in comparison with most livestock species, such as pigs or cattle, but also by a lack of reliable expected progeny differences and phenotypic values associated to the variations in fertility in the species.

Laseca and her colleagues noted that, although the use of genomic methods in horses has increased significantly over the past five years, studies focusing on reproductive traits remain few and far between.

There are even fewer which aim to dissect and quantify more accurately the influence of the genetic background and the environment in the expression of the observable traits, they noted.

Horse genomics is currently undergoing an exponential expansion, not least due to the adaptation of new genomic methodologies to the species, the existence of a new, accurate reference genome, and the exponential increase in the number of equines which have been genotyped.

It is, therefore, highly likely that our knowledge of the reproductive architecture of horses will grow considerably over the next few years.

However, large-scale datasets of reproductive phenotypes are still scarce in horses, probably due to the lack of availability of reliable reproductive phenotypes (particularly in mares).

Therefore, the development of new phenotypes to measure reproductive fitness more objectively and their systematic use by breeder associations are essential to allow a more in-depth study of the reproductive function in horses.

In addition, the search for candidate genes is a highly promising way to obtain a better understanding of the processes involved in horse fertility.

They not only can help to elucidate which physiological functions could be affected by a specific genotype, but also to predict which genotypes could be more affected by environmental challenges, and they can be integrated into breeding programs to detect, even at very young ages, the potential fertility (increased, normal, or decreased) of a given mare or stallion.

The authors said the lack of consistency observed in candidate genes associated with fertility detected in different breeds or populations of horses, (most of them detected by a single study) will be reduced only with an increase in the volume of evidence gathered.

In this sense, only 11 genes reviewed in their paper were detected by two or more studies, and only five were detected using more than one approach.

It was recently shown that combined genomic approaches in the same study can increase accuracy and reliability in detecting candidate genes. However, no combined studies have yet been reported in horses. Such combined approaches would constitute the best approach in our search for a better, more reliable understanding of genetic effects on horse fertility.

The review team comprised Laseca, Gabriel Anaya, Zahira Pea and Antonio Molina, with the University of Crdoba in Spain; and Yamila Pirosanto and Sebastin Demyda Peyrs, with the National University of La Plata and the Higher Council for Scientific and Technological Research, both in La Plata, Argentina.

Laseca, N.; Anaya, G.; Pea, Z.; Pirosanto, Y.; Molina, A.; Demyda Peyrs, S. Impaired Reproductive Function in Equines: From Genetics to Genomics. Animals 2021, 11, 393. https://doi.org/10.3390/ani11020393

The review, published under a Creative Commons License, can be read here.

View original post here:
Window into the genetics behind equine reproduction grows ever wider, say researchers - Horsetalk

Genetics

Animal Genetics Market to Witness Robust Expansion by 2027 with Top Key players like Genus Plc, Hendrix Genetics, Ew Group Gmbh, Grimaud Groupe, Alta…

February 5, 2021 medical

Animal genetics refers to the branch of genetics that deals with the study of inheritance and gene variation in domestic and wild animals. This involves gene expression, animal breeding and physical genetic traits such as coat color, body structure, facial shape, and others which is entirely based on heredity. Animal genetics are used for DNA testing, genetic trait testing, and genetic disease training. The animal genetics market is anticipated to increase due to the rapid demand, consumption of animal proteins, and increase in urban population, which exhibits demand for meat products across the globe during the forecast period.

The global Animal Genetics Market size is expected to Expand at Significant CAGR of +6% during forecast period (2021-2027).

The report on the global Animal Genetics market is a complete overview of the market, covering various aspects product definition, segmentation based on various parameters, and the prevailing vendor landscape. It compiles in-depth information and research methodologies. It is also combined with relevant charts and tables to enable readers to get a better perspective of this global market.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=137222

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this Report:

Genus Plc, Hendrix Genetics, Ew Group Gmbh, Grimaud Groupe, Alta Genetics, Inc., Crv Holding B.V., Neogen Corporation, Zoetis, Inc., Envigo (Harlan Laboratories, Inc.), Animal Genetics Inc., Vetgen.

This report provides a detailed and analytical look at the various companies that are working to achieve a high market share in the global Animal Genetics market. Data is provided for the top and fastest growing segments. This report implements a balanced mix of primary and secondary research methodologies for analysis. Markets are categorized according to key criteria. To this end, the report includes a section dedicated to the company profile. This report will help you identify your needs, discover problem areas, discover better opportunities, and help all your organizations primary leadership processes. You can ensure the performance of your public relations efforts and monitor customer objections to stay one step ahead and limit losses.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Animal Genetics market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Animal Genetics market.

Get Up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=137222

The report gathers the essential information including the new strategies for growth of the industry and the potential players of the global Animal Genetics Market. It enlists the topmost industry player dominating the market along with their contribution to the global market. The report also demonstrates the data in the form of graphs, tables, and figures along with the contacts details and sales of key market players in the global Animal Genetics Market.

Global Animal Genetics Market Segmentation:

Market Segmentation: By Type

Market Segmentation: By Application

For extensive comprehension of market dynamics, the Animal Genetics Market is bifurcated among various regions:

Years considered for this report:

Table of Contents

Global Animal Genetics Market Research Report 2021 2027

Chapter 1 Animal Genetics Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Animal Genetics Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=137222

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

See the article here:
Animal Genetics Market to Witness Robust Expansion by 2027 with Top Key players like Genus Plc, Hendrix Genetics, Ew Group Gmbh, Grimaud Groupe, Alta...

Genetics

JK Agri Genetics reports standalone net loss of Rs 2.70 crore in the December 2020 quarter – Business Standard

February 5, 2021 medical

Sales rise 9.57% to Rs 34.47 crore

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, February 05 2021. 17:52 IST

More here:
JK Agri Genetics reports standalone net loss of Rs 2.70 crore in the December 2020 quarter - Business Standard

Genetics

Genetic Testing Market Analysis 2021 with Top Companies, Production, Consumption, Price and Growth Rate 23andMe, Abbott, Ambry, Genetics BGI KSU |…

February 5, 2021 medical

This market study on Genetic Testing Market covers the global and regional market with an in-depth breakdown of the inclusive growth prospects in the market. Also, it sheds light on the wide-ranging competitive landscape of the global Genetic Testing market. It defines about the recent innovations, applications and end users of the market.The report first introduces the market basics like definitions, classifications, applications, and industry chain overview, and then industry policies and plans, product specifications, manufacturing processes, cost structures, and so on.Global Genetic Testing market report lends a hand with businesses to thrive in the market by providing them with an array of insights about the market and the industry. Inputs from various industry experts, essential for the detailed market analysis, have been used very carefully to generate this finest market research report.

Genetic testing market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to reach at an estimated value of 585.81 billion and grow at a CAGR of 11.85% in the above-mentioned forecast period. Increase in incidences of genetic disorders and cancer drives the genetic testing market.

Download Free Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-genetic-testing-market&AS

The major players who are leading the market throughout the globe are:

The Genetic Testing market report comprises of several market dynamics and estimations of the growth rate and the market value based on market dynamics and growth inducing factors. For generation of an excellent market research report, principal attributes such as highest level of spirit, practical solutions, dedicated research and analysis, innovation, talent solutions, integrated approaches, most advanced technology and commitment plays a key role. The report contains reviews about key players in the market, major collaborations, merger and acquisitions along with trending innovation and business policies. While preparing the winning Genetic Testing report, markets on the local, regional as well as global level are explored.

Genetic Testing Market Segmentation:

By Type (Predictive & Presymptomatic Testing, Carrier Testing, Prenatal & Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others)

By Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing)

By Application (Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Others)

By Disease (Alzheimers Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntingtons Disease, Rare Diseases, Other Diseases)

MAJOR TOC OF THE REPORT:-

Get Complete Latest TOC of This Report @ https://www.databridgemarketresearch.com/toc/?dbmr=global-genetic-testing-market&AS

Competitive Landscape and Genetic TestingMarket Share Analysis

Genetic testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to genetic testing market.

The major players covered in the genetic testing market report are 23andMe, Inc., Abbott., Ambry Genetics., BGI, Biocartis, BIO-HELIX, bioMrieux SA, Blueprint Genetics Oy, Cepheid., deCODE genetics, GeneDx, Inc., Exact Sciences Corp, HTG Molecular Diagnostics, Genomictree., Illumina, Inc, Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation., ICON plc, Myriad Genetics, Inc, Natera, Inc., Pacific Biosciences of California, Inc, Pathway Genomics, QIAGEN, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd and Siemens Healthcare Private Limited among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Significant Highlights of the Report:

Centered Study on Strategy, Development & market Scenario

Global Top Companies Share Analysis in Genetic Testing Market

Achieve strategic insights on competitor information to develop powerful industry growth

Identify emerging players and create effective counter-strategies to cross the competitive edge

Identify crucial and various product types/distribution channel offering provided by major players for Genetic Testing market growth

To provide a more accurate market forecast, all our reports will be updated before delivery taking into account the effects of COVID-19.

Global Genetic Testing Market Scope and Market Size

Genetic testing market is segmented on the basis of type, technology, application, disease and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Genetic Testing Market Country Level Analysis:

Make An Enquiry and Ask For Customized Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-genetic-testing-market&AS

About Data Bridge Market Research Private Ltd:

Data Bridge Market ResearchPvt Ltdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.

Contact:

Data Bridge Market Research

US:+1 888 387 2818

UK:+44 208 089 1725

Hong Kong:+852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

More Related Reports:

https://adalidda.com/posts/bA4Kk8kbXGJADPjgw/magnetic-resonance-imaging-mri-systems-market-revenue-and

https://adalidda.com/posts/74ETtPxqPZenMGBMo/ophthalmic-surgical-instruments-market-size-2021-expected-to

https://adalidda.com/posts/Joa6ZD8FJak5GDh7C/optogenetics-actuators-and-sensors-market-insights-product

Continue reading here:
Genetic Testing Market Analysis 2021 with Top Companies, Production, Consumption, Price and Growth Rate 23andMe, Abbott, Ambry, Genetics BGI KSU |...